Literature DB >> 3176876

Course and prognosis of chronic progressive multiple sclerosis. Results of an epidemiological study.

J M Minderhoud1, J H van der Hoeven, A J Prange.   

Abstract

In studies on the natural course of multiple sclerosis (MS), several forms of the disease are distinguished. The most important are the relapsing remitting and the chronic progressive forms. The relationship between these remains unclear. In a prospective epidemiological survey we studied the course of MS using the year in which the chronic-progressive phase started as a landmark. The reliability of this "year of progression" was examined in an observer agreement study. Data were acquired from 342 patients. Progression of the handicap was most rapid in case of a secondary progressive course, female sex, high relapse rate in the preceding remitting phase and "year of progression" at a higher age. Survival after the "year of progression" was lowest in the secondary progressive group. Determining the "year of progression" seems to be significant for the prognosis.

Entities:  

Mesh:

Year:  1988        PMID: 3176876     DOI: 10.1111/j.1600-0404.1988.tb03611.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  14 in total

1.  Relapses and disability accumulation in progressive multiple sclerosis.

Authors:  M Mateo Paz Soldán; Martina Novotna; Nuhad Abou Zeid; Nilufer Kale; Melih Tutuncu; Daniel J Crusan; Elizabeth J Atkinson; Aksel Siva; B Mark Keegan; Istvan Pirko; Sean J Pittock; Claudia F Lucchinetti; Brian G Weinshenker; Moses Rodriguez; Orhun H Kantarci
Journal:  Neurology       Date:  2014-11-14       Impact factor: 9.910

2.  Prognostic criteria in an epidemiological group of patients with multiple sclerosis: an exploratory study.

Authors:  K Lauer; W Firnhaber
Journal:  J Neurol       Date:  1992-02       Impact factor: 4.849

Review 3.  Clinical prognostic factors in multiple sclerosis: a natural history review.

Authors:  Alexandra Degenhardt; Sreeram V Ramagopalan; Antonio Scalfari; George C Ebers
Journal:  Nat Rev Neurol       Date:  2009-12       Impact factor: 42.937

4.  Multiple sclerosis in Finland: incidence trends and differences in relapsing remitting and primary progressive disease courses.

Authors:  M-L Sumelahti; P J Tienari; M Hakama; J Wikström
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-01       Impact factor: 10.154

5.  Clinical study of primary progressive multiple sclerosis in Northern Ireland, UK.

Authors:  G V McDonnell; S A Hawkins
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-04       Impact factor: 10.154

6.  Multivariate analysis of predictive factors of multiple sclerosis course with a validated method to assess clinical events.

Authors:  M Trojano; C Avolio; C Manzari; A Calò; F De Robertis; G Serio; P Livrea
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-03       Impact factor: 10.154

Review 7.  Primary progressive multiple sclerosis : current and future treatment options.

Authors:  Siobhan M Leary; Alan J Thompson
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

8.  Multiple sclerosis with a progressive course from onset in Lorraine-Eastern France.

Authors:  M Debouverie; S Louis; S Pittion-Vouyovitch; T Roederer; H Vespignani
Journal:  J Neurol       Date:  2007-06-25       Impact factor: 4.849

9.  An immunogenetic heterogeneity in multiple sclerosis.

Authors:  J Hillert; M Grönning; H Nyland; H Link; O Olerup
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-10       Impact factor: 10.154

10.  Cytokine Profile in Patients with Progressive Multiple Sclerosis and Its Association with Disease Progression and Disability.

Authors:  Ana Paula Kallaur; Sayonara Rangel Oliveira; Andréa Name Colado Simão; Daniela Frizon Alfieri; Tamires Flauzino; Josiane Lopes; Wildea Lice de Carvalho Jennings Pereira; Caio de Meleck Proença; Sueli Donizete Borelli; Damacio Ramón Kaimen-Maciel; Michael Maes; Edna Maria Vissoci Reiche
Journal:  Mol Neurobiol       Date:  2016-03-29       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.